Pablo Macaya-Aja
A Coruna, GA, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2.
Journal: Antimicrobial agents and chemotherapy
Published: August 19, 2026
FTIR typing of the emerging NDM-14-producing Klebsiella pneumoniae ST147 clone.
Journal: Journal of clinical microbiology
Published: August 13, 2026
Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam.
Journal: Antimicrobial agents and chemotherapy
Published: March 27, 2026
Emergence of New Delhi Metallo-β-Lactamase 14-Producing Klebsiella pneumoniae Sequence Type 147 Clone in Spain and Outbreak in the Canary Islands.
Journal: Emerging infectious diseases
Published: January 30, 2026
Microbiome differential abundance methodologies to detect relevant taxa associated with chemotherapy toxicity rate in colorectal cancer.
Journal: Bioinformatics advances
Published: November 11, 2025
Enterococcus thailandicus: Genomic evidence of a potential new player in enterococcal virulence and antimicrobial resistance.
Journal: New microbes and new infections
Published: September 09, 2025
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.
Journal: Antimicrobial agents and chemotherapy
Published: July 25, 2025
In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Mycobacterium abscessus Complex Isolates.
Journal: Antibiotics (Basel, Switzerland)
Published: June 04, 2025
In vivo evolution of resistance to novel β-lactam/β-lactamase inhibitor combinations through overproduction of the horizontally acquired extended-spectrum AmpC β-lactamase FOX-14 and porin disruption in Serratia marcescens.
Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Published: May 14, 2025
Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS.
Journal: Journal of clinical microbiology
Published: March 25, 2025
Last Updated: 09/26/2026